

Elanix Biotechnologies AG

Elanix Biotechnologies AG**WKN:** A0WMJQ **ISIN:** DE000A0WMJQ4 **Land:** Deutschland

Nachricht vom 22.08.2017 | 14:23

ELANIX BIOTECHNOLOGIES AG STARTS DUE DILIGENCE TO ACQUIRE A FETAL PROGENITOR BONE CELL LINE WITHIN A CAPITAL INCREASE BY WAY OF CONTRIBUTION IN KIND

Elanix Biotechnologies AG / Key word(s): Capital Increase

22-Aug-2017 / 14:23 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

ELANIX BIOTECHNOLOGIES AG STARTS DUE DILIGENCE TO ACQUIRE A FETAL PROGENITOR BONE CELL LINE WITHIN A CAPITAL INCREASE BY WAY OF CONTRIBUTION IN KIND

Berlin, 22 August 2017 - The CEO of Elanix Biotechnologies AG ("company", "Elanix", FRA: ELN) strives to fully acquire Swiss Inno 4 Cell AG within a capital increase, by way of contribution in kind ("transaction") using the existing Authorized Capital. Inno 4 Cell AG owns a fetal progenitor bone cell line developed by Prof. Lee Ann Laurent Applegate in the context of long-term research work and which would further strengthen the company's product portfolio. In addition to increasing synergies in product development, as a result of the transaction, Elanix expects to offer international licensing agreements to a greater extent in the future.

The transaction is scheduled to be executed at the earliest after the capital increase for cash as to be resolved next AGM (24 August 2017) and is, amongst other things, subject to successful due diligence at Inno 4 Cell AG. Following today's fundamental agreement, Elanix will continue negotiations with the management of Inno 4 Cell AG in order to determine further details of the transaction, in particular on the value of the contribution in kind, which shall be determined by an external valuation.

The company will disclose further details in due course.

Tomas Svoboda
CEO

Investore.relations@elanix-bt.com

About Elanix

Elanix Biotechnologies AG (FRA: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix is headquartered in Nyon, Switzerland, with its registered office in Potsdam, Germany, and listed on the Frankfurt Stock Exchange under the symbol ELN. For more information, visit www.elanixbiotechnologies.com.

Disclaimer / Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

22-Aug-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English

Company: Elanix Biotechnologies AG
Domstr. 22
14482 Potsdam
Germany

ISIN: DE000A0WMJQ4

WKN: A0WMJQ

Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf

End of Announcement

DGAP News Service

DGAP – ein Service der EQS Group AG

[Twitter](#) | [Impressum](#) | [AGB](#) | [Rechtliche Hinweise & Datenschutz](#)